WEBULL

Shionogi (TSE:4507) Looks Cheap After FDA Accepts Cefiderocol Pediatric sNDA

Simply Wall St · 2d ago

Why the FDA sNDA for cefiderocol matters for Shionogi stock

The FDA sNDA acceptance for Shionogi (TSE:4507) antibiotic cefiderocol in pediatric hospital and urinary infections highlights a fresh regulatory milestone that could influence how investors think about the company s long term revenue mix.

See our latest analysis for Shionogi.

Investors have seen Shionogi s share price gain 3.45% over the past month, even after a roughly 10.49% decline over 90 days. At the same time, the 1 year total shareholder return of 18.12% and 3 year total shareholder return of 57.78% point to solid longer term gains as the cefiderocol story develops.

If this kind of specialty healthcare catalyst interests you, it could be worth seeing what else is moving in the sector through the 7 healthcare AI stocks.

Shionogi’s recent share price gain over the past month, set against a weaker 90-day patch, raises a simple question: are investors reassessing the underlying cefiderocol opportunity, or simply reacting to sentiment as valuation comes into focus?

Price to earnings of 11.9x for Shionogi: Is it justified?

On simple earnings terms, Shionogi trades on a P/E of 11.9x, which screens as inexpensive when set against both its peers and the wider JP pharmaceuticals sector.

The P/E ratio compares the current share price to annual earnings per share and gives you a quick sense of how much investors are paying for each unit of profit. For a company like Shionogi, with an established prescription drugs franchise and consistent profitability, P/E is often a primary yardstick that investors watch closely when they are weighing up whether the current price reflects those earnings.

Here, the 11.9x P/E sits well below the JP pharmaceuticals industry average of 16.6x and also below the peer average of 20.3x. This points to a clear discount on an earnings basis. Against an estimated fair P/E of 22.3x, the current multiple is even further behind a level the market could move towards if sentiment and expectations align more closely with those implied by the fair ratio.

Explore the SWS fair ratio for Shionogi

Result: Price to earnings of 11.9x (UNDERVALUED)

However, Shionogi’s cefiderocol narrative still faces risks, including regulatory outcomes around pediatric indications and potential shifts in competitive antibiotic pricing that could affect future earnings assumptions.

Find out about the key risks to this Shionogi narrative.

Another view on Shionogi using our DCF model

While the 11.9x P/E suggests Shionogi trades at a discount to peers, the SWS DCF model indicates an even larger value gap, with the share price at ¥2,876 compared with an estimated future cash flow value of ¥6,169.39. If both signals point to undervaluation, what might the market be missing?

Look into how the SWS DCF model arrives at its fair value.

4507 Discounted Cash Flow as at Jul 2026
4507 Discounted Cash Flow as at Jul 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Shionogi for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 18 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mix of cautious and optimistic signals around Shionogi leaves you undecided, it makes sense to move quickly and test the numbers yourself. A good place to start is the 5 key rewards.

Looking for more Shionogi style investment ideas?

If Shionogi has sharpened your interest in focused stock ideas, do not stop here, broaden your watchlist with other targeted opportunities built from the same data driven process.

  • Target dependable income streams by checking stocks screened as potential 48 dividend fortresses for investors who care about yield and resilience.
  • Hunt for strong businesses at appealing prices by reviewing companies identified in the 18 high quality undervalued stocks and see which ones fit your criteria.
  • Prioritize capital protection by focusing on companies highlighted in the 51 resilient stocks with low risk scores so you are not the last to spot resilient opportunities.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.